Table 2 Comparison of clinicopathological features between EBV-associated early gastric carcinoma with and without lymphoid stroma
Feature | EBV-associated early gastric carcinoma with lymphoid stroma (n = 8) | Conventional early gastric carcinoma without lymphoid stroma (n = 109) | |||||
|---|---|---|---|---|---|---|---|
intramucosa (n = 50) | P | Superficial submucosa (SM1) (n = 28) | P | Deep submucosa (SM2) (n = 31) | P | ||
Age (year) | Â | Â | 0.834 | Â | 0.896 | Â | 0.875 |
 Median | 64.5 | 62 |  | 61 |  | 61 |  |
Gender | Â | Â | 0.172 | Â | 0.076 | Â | 0.168 |
 Male | 8 (100.0%) | 35 (70.0%) |  | 18 (64.3%) |  | 23 (74.2%) |  |
 Female | 0 (0.0%) | 15 (30.0%) |  | 10 (35.7%) |  | 8 (25.8%) |  |
Location | Â | Â | 0.066 | Â | 0.176 | Â | 0.262 |
 Cardia-fundus | 4 (50.0%) | 10 (20.0%) |  | 7 (25.0%) |  | 9 (29.0%) |  |
 Corpus-antrum-angularis | 4 (50.0%) | 40 (80.0%) |  | 21 (75.0%) |  | 22 (71.0%) |  |
Macroscopic pattern | Â | Â | 1.000 | Â | 1.000 | Â | 0.686 |
 Non-ulcerated | 6 (75.0%) | 39 (78.0%) |  | 19 (67.9%) |  | 19 (61.3%) |  |
 Ulcerated | 2 (25.0%) | 11 (22.0%) |  | 9 (32.1%) |  | 12 (38.7%) |  |
Tumor size (cm) | Â | Â | 0.809 | Â | 0.864 | Â | 0.275 |
 Mean ± SD | 2.2 ± 0.7 | 2.1 ± 1.0 |  | 2.1 ± 0.7 |  | 2.6 ± 1.1 |  |
Tumor differentiation | Â | Â | 0.000 | Â | 0.003 | Â | 0.001 |
 Well/moderate | 0 (0.0%) | 37 (74.0%) |  | 21 (75.0%) |  | 20 (64.5%) |  |
 Poorly | 8 (100.0%) | 13 (26.0%) |  | 7 (25.0%) |  | 11 (35.5%) |  |
Lymphovascular invasion | Â | Â | 0.259 | Â | 1.000 | Â | 0.400 |
 Absent | 7 (87.5%) | 49 (98.0%) |  | 25 (89.3%) |  | 21 (67.7%) |  |
 Present | 1 (12.5%) | 1 (2.0%) |  | 3 (10.7%) |  | 10 (32.3%) |  |
Perineural invasion | Â | Â | NA | Â | NA | Â | 1.000 |
 Absent | 8 (100%) | 50 (100%) |  | 28 (100%) |  | 28 (90.3%) |  |
 Present | 0 (0%) | 0 (0%) |  | 0 (0%) |  | 3 (9.7%) |  |
Lymph node metastasis | Â | Â | 1.000 | Â | 0.566 | Â | 0.042 |
 Absent | 8 (100%) | 48 (96%) |  | 23 (82.1%) |  | 19 (61.3%) |  |
 Present | 0 (0%) | 2 (4%) |  | 5 (17.9%) |  | 12 (38.7%) |  |
Pathologic stage | Â | Â | 1.000 | Â | 1.000 | Â | 0.168 |
 I | 8 (100%) | 49 (98%) |  | 26 (92.9%) |  | 23 (74.2%) |  |
 II | 0 (0%) | 1 (2%) |  | 2 (7.1%) |  | 8 (25.8%) |  |
Synchronous tumor | Â | Â | 0.001 | Â | 0.005 | Â | 0.001 |
 Absent | 4 (50%) | 49 (98%) |  | 27 (96.4%) |  | 31 (100%) |  |
 Present | 4 (50%) | 1 (2%) |  | 1 (3.6%) |  | 0 (0%) |  |